DK2120875T3 - Fremgangsmåde til terapeutisk administration af dhe med henblik på at muliggøre hurtig lindring af migræne samtidig med minimering af bivirkningsprofilen - Google Patents

Fremgangsmåde til terapeutisk administration af dhe med henblik på at muliggøre hurtig lindring af migræne samtidig med minimering af bivirkningsprofilen Download PDF

Info

Publication number
DK2120875T3
DK2120875T3 DK08725456.1T DK08725456T DK2120875T3 DK 2120875 T3 DK2120875 T3 DK 2120875T3 DK 08725456 T DK08725456 T DK 08725456T DK 2120875 T3 DK2120875 T3 DK 2120875T3
Authority
DK
Denmark
Prior art keywords
dhe
dihydroergotamine
administration
migraine
cmax
Prior art date
Application number
DK08725456.1T
Other languages
English (en)
Inventor
Nabih N Ramadan
Thomas A Armer
Robert O Cook
Stephen B Shrewsbury
Original Assignee
Map Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Map Pharmaceuticals Inc filed Critical Map Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2120875T3 publication Critical patent/DK2120875T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)

Claims (11)

1. Forbindelse, der er dihydroergotamin eller et salt, et hydrat, en polymorf eller et ionpar deraf til anvendelse ved en fremgangsmåde til behandling af migræne hos et menneskeindivid; hvor behandlingen omfatter afgivelse via lungeinhalation ved hjælp af en indretning, som omfatter en tørpulverinhalator, forstøver, fordamper, tryksat inhalator til afmålte doser eller åndedrætsaktiveret tryksat inhalator til afmålte doser, af en samlet dosis af dihydroergotamin eller et salt, et hydrat, en polymorf eller et ionpar deraf på fra 0,1 til 10 mg pr. migræneanfald; og hvor dosen er i en fast eller flydende formulering eller aerosolformulering, der er tilpasset til administration ved hjælp af indretningen med henblik på at administrere dihydroergotaminet eller et salt, et hydrat, en polymorf eller et ionpar deraf ved en sådan hastighed, at topplasmakoncentrationen (Cmax) af dihydroergotamin er mindre end 15.000 pg/ml, og tiden til Cmax (T max) af dihydroergotamin er mindre end 20 minutter efter administration.
2. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvorTmax af dihydroergotamin er inden for 15 minutter efter administration.
3. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor den samlede dosis ligger i intervallet fra 0,5 mg til 5,0 mg.
4. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor dihydroergotaminet, saltet, hydratet, polymorfen eller ionparret deraf administreres i en enhedsdosis på mindre end 3,0 mg.
5. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor den samlede dosis ligger i intervallet fra 1,0 mg til 2,0 mg.
6. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor indretningen er en inhalatorindretning, som omfatter én eller flere enhedsdoser af en formulering af dihydroergotamin eller et salt, et hydrat, en polymorf eller et ionpar deraf, hvor hver enhedsdosis administreres ved en sådan hastighed, at Cmax er mindre end 10.000 pg/ml, og Tmax er mindre end 20 minutter efter administration.
7. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvilken forbindelse omfatter dihydroergotaminmesylat.
8. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor fremgangsmåden omfatter administration af forbindelsen ved hjælp af en indretning, som omfatter en åndedrætsaktiveret tryksat inhalator til afmålte doser.
9. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor fremgangsmåden omfatter administration af forbindelsen ved hjælp afen indretning, som omfatter en tørpulverinhalator.
10. Forbindelse ifølge krav 1 til anvendelse ifølge krav 1, hvor formuleringen administreres til individet ved hjælp afen åndedrætsaktiveret inhalator til afmålte doser, hvor dihydroergotaminet eller et salt, et hydrat, en polymorf eller et ionpar deraf administreres ved en sådan hastighed, at topplasmakoncentrationen af dihydroergotamin (Cmax) er mindre end 10.000 pg/ml koncentration, og tiden (T max ) efter administration, når topplasmakoncentrationen opnås, er mindre end 20 minutter efter administration, og hvor formuleringen administreres uden administration af et antiemetikum.
11. Anvendelse af en forbindelse, der er dihydroergotamin eller et salt, et hydrat, en polymorf eller et ionpar deraf ved fremstilling af et medikament til behandling af migræne hos et menneskeindivid; hvor behandlingen omfatter afgivelse via lungeinhalation ved hjælp afen indretning, som omfatter en tørpulverinhalator, forstøver, fordamper, tryksat inhalator til afmålte doser eller åndedrætsaktiveret tryksat inhalator til afmålte doser, af en samlet dosis af dihydroergotamin eller et salt, hydrat, polymorf eller ionpar deraf på fra 0,1 til 10 mg pr. migræneanfald; og hvor dosen er i en fast eller flydende formulering eller aerosolformulering, der er tilpasset til administration ved hjælp af indretningen med henblik på at afgive dihydroergotamin eller et salt, hydrat, polymorf eller ionpar deraf ved en sådan hastighed, at topplasmakoncentrationen (Cmax) af dihydroergotamin er mindre end 15.000 pg/ml, og tiden til Cmax (Tmax) af dihydroergotamin er mindre end 20 minutter efter administration.
DK08725456.1T 2007-02-11 2008-02-11 Fremgangsmåde til terapeutisk administration af dhe med henblik på at muliggøre hurtig lindring af migræne samtidig med minimering af bivirkningsprofilen DK2120875T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90085007P 2007-02-11 2007-02-11
PCT/US2008/001829 WO2008097664A1 (en) 2007-02-11 2008-02-11 Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile

Publications (1)

Publication Number Publication Date
DK2120875T3 true DK2120875T3 (da) 2018-10-22

Family

ID=39400937

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08725456.1T DK2120875T3 (da) 2007-02-11 2008-02-11 Fremgangsmåde til terapeutisk administration af dhe med henblik på at muliggøre hurtig lindring af migræne samtidig med minimering af bivirkningsprofilen
DK11191794.4T DK2425820T3 (da) 2007-02-11 2008-02-11 Fremgangsmåde til terapeutisk administration af dhe for at muliggøre hurtig lindring af migræne, mens bivirkningsprofilen minimeres

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11191794.4T DK2425820T3 (da) 2007-02-11 2008-02-11 Fremgangsmåde til terapeutisk administration af dhe for at muliggøre hurtig lindring af migræne, mens bivirkningsprofilen minimeres

Country Status (19)

Country Link
US (10) US8148377B2 (da)
EP (3) EP2425820B1 (da)
JP (4) JP5825757B2 (da)
KR (3) KR20150041804A (da)
CN (2) CN101677954A (da)
AU (3) AU2008214205B2 (da)
CA (1) CA2677838C (da)
CY (1) CY1116546T1 (da)
DK (2) DK2120875T3 (da)
ES (2) ES2538082T3 (da)
HK (1) HK1204918A1 (da)
HU (1) HUE026884T2 (da)
IL (1) IL200333A (da)
MX (1) MX2009008582A (da)
PL (1) PL2425820T3 (da)
PT (1) PT2425820E (da)
SI (1) SI2425820T1 (da)
WO (1) WO2008097664A1 (da)
ZA (1) ZA200905628B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
CA2538237A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
EP2425820B1 (en) 2007-02-11 2015-04-08 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
CN101980738A (zh) 2008-02-07 2011-02-23 华盛顿大学 圆周气雾设备
US20110082150A1 (en) * 2008-02-11 2011-04-07 Robert Owen Cook Headache pre-emption by dihydroergotamine treatment during headache Precursor events
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
BR122021002471B8 (pt) 2011-03-03 2022-10-25 Impel Neuropharma Inc Dispositivo de distribuição de droga nasal
RU2741249C2 (ru) 2011-05-09 2021-01-22 Импел Ньюрофарма Инк. Наконечники для назальной доставки лекарственных средств
CN103827113A (zh) 2011-06-23 2014-05-28 Map药物公司 新型氟麦角碱类似物
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
AU2012355983A1 (en) 2011-12-21 2015-01-22 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US20140179707A1 (en) * 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel ergoline derivatives and uses thereof
WO2014100351A2 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
WO2014100353A1 (en) * 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
CA2909954C (en) 2013-04-28 2021-03-23 Impel Neuropharma, Inc. Medical unit dose container
CA2998182A1 (en) 2015-09-10 2017-03-16 Impel Neuropharma, Inc. In-line nasal delivery device
EP3713628A4 (en) 2017-11-21 2021-08-18 Impel Neuropharma Inc. INTRA-NASAL DEVICE WITH DIVER TUBE
JP2021503988A (ja) 2017-11-21 2021-02-15 インペル ニューロファーマ インコーポレイテッド インレットインターフェースを用いた鼻腔内装置
CA3088942C (en) * 2018-01-05 2023-01-03 Impel Neuropharma, Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
KR20200118034A (ko) 2018-01-05 2020-10-14 임펠 뉴로파마 인코포레이티드 정밀 후각기관 장치에 의한 올란자핀의 비강내 전달
US11083712B1 (en) * 2018-03-20 2021-08-10 Relevale, Inc. Low concentration delivery of an ergoline derivative for treatment of a headache
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
CN113423400A (zh) * 2018-12-11 2021-09-21 小蜜橘制药公司 用于治疗或预防头痛的组合物、装置和方法
CN113473967B (zh) 2019-01-03 2022-09-09 英倍尔制药公司 经鼻药物递送装置
BR112021023049A8 (pt) 2019-05-17 2022-10-18 Impel Neuropharma Inc Dispositivo de dispensação nasal de uso único
US11786512B2 (en) 2019-09-23 2023-10-17 Slayback Pharma Llc Stable pharmaceutical compositions of dihydroergotamine mesylate
US20230043204A1 (en) * 2019-12-23 2023-02-09 Scienture, Inc. Dihydroergotamine mesylate formulations and pre-filled injectors for therapeutic delivery of the same
CN115279371A (zh) * 2020-01-14 2022-11-01 英倍尔制药公司 重复施用双氢麦角胺治疗频繁偏头痛
CA3210442A1 (en) * 2021-03-03 2022-09-09 Jason M. Perry Dihydroergotamine dry powder formulations and methods of use

Family Cites Families (360)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147389A (en) * 1874-02-10 Improvement in sawing-machines
US605674A (en) 1898-06-14 Combined pencil-case and comb-case
BE555319A (da) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
BE556587A (da) 1957-01-31 1957-04-11
US2865427A (en) 1957-05-10 1958-12-23 Robert E Garfield Sliding automobile seat attachment
BE629985A (da) * 1962-11-29
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3261748A (en) * 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3897779A (en) * 1973-06-27 1975-08-05 American Cyanamid Co Triamcinolone acetonide inhalation therapy
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US3994421A (en) * 1975-09-29 1976-11-30 American Cyanamid Company Unitary therapeutic aerosol dispenser
FI770215A (da) 1976-01-30 1977-07-31 Fisons Ltd
US4405598A (en) 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
JPS5325284A (en) 1976-08-19 1978-03-08 Daikin Ind Ltd Aerosol composition
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
GB2001334B (en) 1977-07-19 1982-03-03 Fisons Ltd Pressurised aerosol formulation
US4129603A (en) * 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
US4241048A (en) 1979-05-01 1980-12-23 Bristol-Myers Company Suspension composition of benzocaine
IT1121513B (it) 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
US4352789A (en) 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
EP0050650A1 (en) 1980-04-21 1982-05-05 University Of Southern California Prolonged action drug formulation
EP0039369B1 (en) 1980-05-02 1983-06-15 Schering Corporation Beclomethasone ester solvates, process for their preparation, and preparation of a formulation
DE3017101C2 (de) 1980-05-03 1983-07-21 PS Pharma Maschinen und Geräte GmbH, 6800 Mannheim Dragierwand
FI63672C (fi) 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
US4311863A (en) 1980-06-11 1982-01-19 E. I. Du Pont De Nemours & Company Process for the manufacture of 1,1,1,2-tetrafluoroethane
GB2078422B (en) 1980-06-19 1983-12-21 Standard Telephones Cables Ltd Matrix addressing of display devices
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4423099A (en) 1980-07-28 1983-12-27 Ciba-Geigy Corporation Membrane modified hydrogels
AU548467B2 (en) 1980-08-12 1985-12-12 Glaxo Group Limited Tryptamines and their isoindolylethyl derivatives
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
DE3268533D1 (en) 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
GB2105189B (en) 1981-07-24 1985-03-20 Fisons Plc Inhalation drugs
KR890000664B1 (ko) 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
JPS5921613A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4582731A (en) 1983-09-01 1986-04-15 Battelle Memorial Institute Supercritical fluid molecular spray film deposition and powder formation
HU196752B (en) 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
US4514574A (en) 1984-01-09 1985-04-30 The Dow Chemical Company Process for separating isomeric mixtures
JPS60224638A (ja) 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
JPS60227805A (ja) 1984-04-26 1985-11-13 Mitsubishi Plastics Ind Ltd 複合ダイヤフラム
US4629478A (en) 1984-06-22 1986-12-16 Georgia Tech Research Corporation Monodisperse aerosol generator
IE59086B1 (en) 1984-07-25 1994-01-12 Hovione Int Ltd Preparation and use of new solvates of beclomthasone 17,21-dipropionate
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US5069911A (en) 1985-02-05 1991-12-03 Sandoz Ltd. Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5021428A (en) 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US4737384A (en) 1985-11-01 1988-04-12 Allied Corporation Deposition of thin films using supercritical fluids
NZ221411A (en) 1986-08-11 1989-10-27 Innovata Biomed Ltd Pharmaceutical compositions containing microcapsules and a surfactant
US5200413A (en) 1987-01-05 1993-04-06 Beecham Group P.L.C. Indolyl carboxamides useful treating migraine, cluster headache, trigeminal neuralgia or emesis
US4767612A (en) 1987-01-23 1988-08-30 Rorer Pharmaceutical Corporation Triamcinolone acetonide for the treatment of allergic rhinitis
US4851595A (en) 1987-07-07 1989-07-25 E. I. Du Pont De Nemours And Company Liquid phase halogen exchange process for the manufacture of 1,1,1,2-tetrafluoroethane
IT1222509B (it) 1987-08-17 1990-09-05 Miat Spa Insufflatore per la somministrazione di farmaci sotto forma di polvere predosata in opercoli
US5364863A (en) 1987-09-08 1994-11-15 Eli Lilly And Company Specific 5-HT3 antagonists
US4963557A (en) 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
EP0321607B1 (en) 1987-12-21 1993-09-22 Union Carbide Corporation Supercritical fluids as diluents in liquid spray application of coatings
DE3744329A1 (de) 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
JPH01176437A (ja) 1987-12-29 1989-07-12 Ono Pharmaceut Co Ltd 有機物質の微粒化方法
DE3823378A1 (de) 1988-07-09 1990-01-11 Knoll Ag (s)-emopamil zur anwendung bei der behandlung von migraene
US5066522A (en) 1988-07-14 1991-11-19 Union Carbide Chemicals And Plastics Technology Corporation Supercritical fluids as diluents in liquid spray applications of adhesives
US5206268A (en) 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB8820398D0 (en) 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
WO1990003782A2 (en) 1988-10-05 1990-04-19 The Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828544D0 (en) 1988-12-07 1989-01-11 Ici Plc Chemical process
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
DE3905726A1 (de) 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
SE466684B (sv) 1989-03-07 1992-03-23 Draco Ab Anordning vid en inhalator samt foerfarande foer att med anordningen registrera medicinering med inhalator
GB8908250D0 (en) 1989-04-12 1989-05-24 Fisons Plc Formulations
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
ES2087911T3 (es) 1989-04-28 1996-08-01 Riker Laboratories Inc Dispositivo de inhalacion de polvo seco.
US4945119A (en) 1989-05-10 1990-07-31 The Dow Chemical Company Foaming system for rigid urethane and isocyanurate foams
US4940171A (en) 1989-05-18 1990-07-10 Gilroy Gordon C Aerosol package having compressed gas propellant and vapor tap of minute size
US5176878A (en) 1989-05-23 1993-01-05 Teledyne Industries, Inc. Zirconium-hafnium separation process
AU633584B2 (en) 1989-06-15 1993-02-04 Tokyo Tanabe Company Limited Aerosols of pyrido(1,2-a)pyrimidine compounds
US5232707A (en) 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
US4916125A (en) 1989-07-11 1990-04-10 Sandoz Ltd. Method of treating migraine
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
DE69033389T2 (de) 1989-08-18 2000-07-06 Foster Miller Inc Behälterbau
GB8918879D0 (en) 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
US5225163A (en) 1989-08-18 1993-07-06 Angenics, Inc. Reaction apparatus employing gravitational flow
US5238920A (en) 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
GB2235627B (en) 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5106659A (en) 1989-10-04 1992-04-21 Nordson Corporation Method and apparatus for spraying a liquid coating containing supercritical fluid or liquified gas
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
DE4003270A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
DE4004904A1 (de) 1990-02-16 1990-09-13 Gerhard Brendel Trommel-applikator
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
DE69109284T2 (de) 1990-03-23 1995-08-24 Minnesota Mining & Mfg Verwendung von fluorierten löslichen tensiden zur herstellung von aerosolarzneimitteln mit dosierter abgabe.
US4970093A (en) 1990-04-12 1990-11-13 University Of Colorado Foundation Chemical deposition methods using supercritical fluid solutions
US5123924A (en) * 1990-04-25 1992-06-23 Spire Corporation Surgical implants and method
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
YU48855B (sh) 1990-06-07 2002-06-19 The Wellcome Foundation Limited Heterociklična jedinjenja i njihovi derivati koji su modifikatori dejstva 5-hidroksi-triptamina i postupak njihovog dobijanja
DE69112917T2 (de) 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US5273579A (en) 1990-06-19 1993-12-28 Mitsubishi Mining And Cement Co., Ltd. Quick setting compositions
CA2020018A1 (en) 1990-06-27 1991-12-28 Don L. Simmons Method and composition for treating the migraine complex
DE69101639T2 (de) 1990-06-27 1994-10-06 Minnesota Mining & Mfg Anwendung von löslichen fluorhaltigen tensiden zur herstellung von aerosol-präparaten mit dosierter abgabe.
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
PT98105B (pt) 1990-06-28 1998-11-30 Glaxo Inc Processo para a preparacao de formulacoes em aerossol contendo como propulsor 1,1,1,2-tetrafluoroetano
EP0756275B1 (en) 1990-06-29 1999-12-15 Sony Corporation Magneto-optical disc recording/reproducing system
HUT63554A (en) 1990-06-29 1993-09-28 Fisons Plc Aerosol preparations under pressure
GB9017155D0 (en) 1990-08-03 1990-09-19 Ici Plc Spray drying
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
ES2064160T3 (es) 1990-10-18 1995-01-16 Minnesota Mining & Mfg Formulacion de aerosol que comprende 17,21-dipropionato de beclometasona.
GB9024365D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9024366D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5919435A (en) 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5254755A (en) 1990-12-04 1993-10-19 Allied-Signal Inc. Partially fluorinated alkanols having a tertiary structure
DE4118230A1 (de) 1990-12-20 1992-06-25 Bayer Ag Verfahren zur isolierung von polymeren aus ihren loesungsmitteln mit kohlendioxid-haltigen fluessigkeiten
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
DE4041563A1 (de) 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
US5317103A (en) 1991-01-15 1994-05-31 Merck Sharp & Dohme Limited Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US5186164A (en) 1991-03-15 1993-02-16 Puthalath Raghuprasad Mist inhaler
US5182040A (en) 1991-03-28 1993-01-26 E. I. Du Pont De Nemours And Company Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
DE4117751A1 (de) 1991-05-30 1992-12-03 Bayer Ag Verfahren zur isolierung von polycarbonaten
CA2111002C (en) 1991-06-10 2000-08-22 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
NZ243062A (en) 1991-06-10 1993-09-27 Schering Corp Aerosol containing medicament and 1,1,1,2-tetrafluoroethane
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
GB9113802D0 (en) 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
EP0592540B1 (en) 1991-07-02 2000-01-26 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
NZ244439A (en) 1991-09-25 1994-01-26 Fisons Plc Pressurised aerosol compositions comprising hydrofluoroalkane, dispersed
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
JP3026841B2 (ja) * 1991-12-12 2000-03-27 グラクソ、グループ、リミテッド 医 薬
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5653962A (en) 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
WO1993011747A1 (en) 1991-12-18 1993-06-24 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
CA2084531A1 (en) 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9200148D0 (en) 1992-01-06 1992-02-26 Minnesota Mining & Mfg Aerosol valves
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US5202110A (en) 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5196575A (en) 1992-02-19 1993-03-23 Hoechst Celanese Corp. Supercritical separation of isomers of functional organic compounds at moderate conditions
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5242949A (en) 1992-03-13 1993-09-07 Rugby-Darby Group Companies, Inc. Treating classic migraine
JPH05280282A (ja) 1992-03-31 1993-10-26 Kubota Corp 埋設管の地中引き込み装置
WO1993025198A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Ultrafine powder for inhalation and production thereof
US5376359A (en) 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US5833950A (en) 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
US5314682A (en) 1992-09-21 1994-05-24 Great Lakes Chemical Corp. Ozone friendly sterilant mixture
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
BR9307346A (pt) 1992-11-02 1999-06-01 Ferro Corp Processo para preparação de materiais de revestimento
GB9226474D0 (en) 1992-12-18 1993-02-10 Ici Plc Production of particulate materials
DK154092D0 (da) 1992-12-23 1992-12-23 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
EP0612697B1 (de) 1993-02-24 1998-01-21 Sulzer Chemtech AG Reinigung von salzbeladenem Abwasser durch Nassoxidation bei superkritischen Bedingungen
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US6162234A (en) 1993-03-23 2000-12-19 Freedland; Yosef Adjustable button cinch anchor orthopedic fastener
ES2194867T3 (es) 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.
BE1006872A6 (nl) 1993-03-26 1995-01-10 Merkus Franciscus W H M Nasale farmaceutische preparaten met dihydroergotamine (dhe).
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
IL105658A (en) 1993-05-11 1995-10-31 Ultrasonic Dryer Ltd Spray drying system
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4322181A1 (de) 1993-06-29 1995-01-12 Hottinger Adolf Masch Vorrichtung und Verfahren zum Greifen eines Gießereikerns, insbesondere eines Sohlenkerns
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
JP3750872B2 (ja) * 1993-07-14 2006-03-01 株式会社小松製作所 車両用エンジンの過給装置およびその制御方法
DE69415998T2 (de) 1993-11-08 1999-08-12 Gillette Co Verfahren zur formung von partikeln unter verwendung einer überkritischen flüssigkeit so hergestellte aerogelpartikel und aerogelpartikel enthaltenden antiperspirantien
EP0655237A1 (de) 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
IT1265473B1 (it) 1993-12-30 1996-11-22 Otefal Srl Procedimento per la produzione di polveri a granulometria controllata e prodotto in polvere cosi' ottenuto
US5468768A (en) 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
SI9400079B (sl) 1994-02-15 2003-02-28 Dr. Weidner Eckhard, Dipl. Ing. Postopek in naprava za pridobivanje in frakcioniranje majhnih delcev iz raztopin nasičenih s plinom
PT748213E (pt) 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
NZ285664A (en) 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
JPH0817132A (ja) 1994-06-30 1996-01-19 Rohm Co Ltd 円盤状情報記録担体の再生装置
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5560543A (en) 1994-09-19 1996-10-01 Board Of Regents, The University Of Texas System Heat-resistant broad-bandwidth liquid droplet generators
GB9419536D0 (en) 1994-09-28 1994-11-16 Glaxo Inc Medicaments
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
DE4438978A1 (de) 1994-10-31 1996-05-02 Helmut Wurzer Elektrochirurgiegerät und Verfahren zu dessen Betrieb
DE59509057D1 (de) 1994-11-07 2001-04-05 Eupec Gmbh & Co Kg Brücken-Modul
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
MX9504934A (es) 1994-12-12 1997-01-31 Morton Int Inc Revestimientos en polvo de pelicula delgada lisa.
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
US6013245A (en) 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
JPH11509433A (ja) 1995-04-14 1999-08-24 グラクソ、ウェルカム、インコーポレーテッド アルブテロール用計量投与用吸入器
EA000889B1 (ru) * 1995-04-14 2000-06-26 Глаксо Веллкам Инк. Дозирующий ингалятор дипропионата беклометазона
RO119116B1 (ro) 1995-04-14 2004-04-30 Glaxo Wellcome Inc. Inhalator pentru dozarea salmeterolului
HU219899B (hu) 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AU709262B2 (en) 1995-10-17 1999-08-26 Board Of Regents, The University Of Texas System Insoluble drug delivery
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
WO1997031691A1 (en) 1996-03-01 1997-09-04 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5776573A (en) 1996-04-16 1998-07-07 Cd Magic, Inc. Compact disc revitalizer formulations and revitalizer
US5648004A (en) 1996-04-19 1997-07-15 Simpson; Claudie Kit and method to retrofit heating elements for curling iron holder
DE19617487A1 (de) 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6284267B1 (en) 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
CZ299790B6 (cs) 1996-08-22 2008-11-26 Skyepharma Canada Inc. Kompozice mikrocástic ve vode nerozpustné látky, farmaceutická kompozice, zpusob prípravy stabilních cástic, mikrocástice ve vode nerozpustné nebo slabe rozpustné slouceniny, kompozice obsahující tyto mikrocástice a zpusob prípravy mikrocástic
US6068832A (en) 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
FR2753639B1 (fr) 1996-09-25 1998-12-11 Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
CN1233954A (zh) 1996-10-01 1999-11-03 西马实验室股份有限公司 掩盖味道的微胶囊组合物及其制备方法
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5813597A (en) 1996-10-15 1998-09-29 Ethicon Endo-Surgery, Inc. Dual orientation dispenser carton
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
IT1291779B1 (it) 1997-02-17 1999-01-21 Magnetek Spa Procedimento per la realizzazione di circuiti stampati e circuiti stampati cosi'ottenuti
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6236747B1 (en) 1997-02-26 2001-05-22 Acuity Imaging, Llc System and method for image subtraction for ball and bumped grid array inspection
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5916125A (en) 1997-05-16 1999-06-29 Allison Engine Company, Inc. Forced purge wave rotor
US6120752A (en) 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
SE9701956D0 (sv) 1997-05-23 1997-05-23 Astra Ab New composition of matter
US6315122B1 (en) 1997-05-29 2001-11-13 Mitsubishi Polyester Film, Llc Palletless packaging system
US6236647B1 (en) 1998-02-24 2001-05-22 Tantivy Communications, Inc. Dynamic frame size adjustment and selective reject on a multi-link channel to improve effective throughput and bit error rate
US6200293B1 (en) 1997-08-27 2001-03-13 Science Incorporated Fluid delivery device with temperature controlled energy source
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
EP1027036A2 (en) 1997-10-03 2000-08-16 ELAN CORPORATION, Plc Taste masked formulations
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6089911A (en) 1997-12-05 2000-07-18 The Whitaker Corporation Apparatus and method for mounting a plurality of surface mount contacts
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
US6120613A (en) 1998-04-30 2000-09-19 Micell Technologies, Inc. Carbon dioxide cleaning and separation systems
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9810126D0 (da) 1998-05-13 1998-07-08 Glaxo Group Ltd
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
SE513162C2 (sv) 1998-07-24 2000-07-17 Allgon Ab Antennanordning
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
EP0989357B1 (en) 1998-09-25 2003-04-02 Stanley Electric Co., Ltd. Headlamp with beam distribution switch mechanism
US5992306A (en) 1998-10-15 1999-11-30 Century Machinery Corp. Structure of a hand holding net basket for frying
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
ES2601855T3 (es) 1998-11-25 2017-02-16 Cima Labs Inc. Comprimido de liberación rápida con núcleo recubierto que contiene el fármaco y capa circundante de enmascaramiento del sabor
GB9825883D0 (en) 1998-11-27 1999-01-20 Aea Technology Plc Formation of monodisperse particles
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
CN1204935C (zh) 1999-01-14 2005-06-08 帝人株式会社 粉末药物多剂量给药器
IL138990A0 (en) 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
HUP0200641A3 (en) 1999-03-26 2002-09-30 Pozen Inc High potency dihydroergotamine compositions
SE9901667D0 (sv) 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
MXPA02002714A (es) * 1999-09-13 2003-10-14 Sheffield Pharmaceuticals Inc Sistema y metodo de control de flujo de aire en aerosol.
US6346323B1 (en) 1999-10-07 2002-02-12 Sig Pack Systems Ag Multi-layer synthetic film
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6367471B1 (en) * 1999-11-01 2002-04-09 Sheffield Pharmaceuticals, Inc. Internal vortex mechanism for inhaler device
US6514481B1 (en) * 1999-11-22 2003-02-04 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
KR100311975B1 (ko) * 1999-12-16 2001-10-17 윤종용 반도체소자 및 그 제조방법
KR20010088139A (ko) 2000-03-10 2001-09-26 백승헌 텍스트 데이터 입력에 대응한 입모양 출력장치 및 그 방법
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0011807D0 (en) 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6620351B2 (en) * 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
US6656492B2 (en) 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
FR2812040B1 (fr) 2000-07-18 2003-02-07 Cit Alcatel Carter monobloc pour pompe a vide
EP1373576A4 (en) 2000-07-24 2005-06-15 Inst Of Molecul & Cell Biology NUCLEIC ACIDS AND METHODS FOR DETECTING VIRAL INFECTION, DISCOVERING CANDIDATE ANTI-VIRAL DRUGS AND DETERMINING DRUG RESISTANCE OF VIRAL ISOLATES
US6941569B2 (en) 2000-08-18 2005-09-06 Hewlett-Packard Development Company, L.P. System and method utilizing a conductive brush for providing power signals to a cartridge access device
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease
WO2002019213A2 (en) 2000-08-30 2002-03-07 Lilly Icos Llc Method for treatment of migraine using pde5 inhibitors
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
FR2815540B1 (fr) 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20030022910A1 (en) 2001-07-05 2003-01-30 R.T. Alamo Ventures I, Inc. Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
TW586963B (en) 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
US20030091513A1 (en) * 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
AU2003208761A1 (en) 2002-02-21 2003-09-09 Amarin Development Ab A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
WO2003075829A2 (en) * 2002-03-08 2003-09-18 M/S. Ind-Swift Limited Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof
DE10212564B4 (de) * 2002-03-12 2007-04-19 Neurobiotec Gmbh 1-Allyl-ergotalkaloid-Derivate und ihre Verwendung zur Prophylaxe und Therapie von Migräne
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
JP2004184809A (ja) 2002-12-05 2004-07-02 Nitto Denko Corp 偏光板の製造方法、偏光板およびそれを用いた画像表示装置
AU2003900081A0 (en) 2003-01-08 2003-01-23 George Moore Drilling jig
GB0300339D0 (en) 2003-01-08 2003-02-05 Bradford Particle Design Ltd Particle formation
GB0300338D0 (en) 2003-01-08 2003-02-05 Bradford Particle Design Ltd Particle formation
GB0304636D0 (en) 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
JP2006525303A (ja) 2003-05-08 2006-11-09 ネクター セラピューティクス ユーケー リミティド 微粒子物質
CA2538237A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
CA2548281C (en) 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20060246070A1 (en) 2004-09-30 2006-11-02 Heavner George A Methods and compositions for treating renal cell carcinoma related pathologies
EP1799264A2 (en) 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Methods and compositions for treating migraine pain
US20090232898A1 (en) 2005-03-28 2009-09-17 Anders Pettersson Pharmaceutical Compositions Useful in the Treatment of Migraine
US7219664B2 (en) * 2005-04-28 2007-05-22 Kos Life Sciences, Inc. Breath actuated inhaler
CA2615378C (en) 2005-07-15 2015-02-17 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
SE530445C2 (sv) 2006-10-23 2008-06-10 Volvo Lastvagnar Ab Hyttupphängningssystem
EP2117506A2 (en) 2006-12-13 2009-11-18 Stephen M. Tuel Methods of making pharmaceutical components for customized drug products
EP2425820B1 (en) * 2007-02-11 2015-04-08 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
US20110119657A1 (en) 2007-12-07 2011-05-19 Martin Vorbach Using function calls as compiler directives
TW200938236A (en) 2008-03-13 2009-09-16 Fei-Peng Lin Deodorization material composition, manufacturing method thereof, and deodorization method
EP2105189A1 (de) 2008-03-27 2009-09-30 Siemens Aktiengesellschaft Verfahren und Vorrichtung zum Abtrennen von Kohlendioxid aus Rauchgas einer fossilbefeuerten Kraftwerksanlage
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
US20100236547A1 (en) * 2008-07-11 2010-09-23 Robert Owen Cook Container for aerosol drug delivery
WO2010148519A1 (en) * 2009-06-25 2010-12-29 Queen's University At Kingston Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist
EP2322326A1 (en) 2009-11-13 2011-05-18 Frederik Daniël Nossbaum Multifunctional tool

Also Published As

Publication number Publication date
US8148377B2 (en) 2012-04-03
AU2008214205A1 (en) 2008-08-14
ZA200905628B (en) 2013-05-29
IL200333A (en) 2017-12-31
CN101677954A (zh) 2010-03-24
US8119639B2 (en) 2012-02-21
JP2016040317A (ja) 2016-03-24
JP2010518095A (ja) 2010-05-27
KR20160106200A (ko) 2016-09-09
AU2016253689A1 (en) 2016-11-24
US20160106669A1 (en) 2016-04-21
EP2425820A1 (en) 2012-03-07
DK2425820T3 (da) 2015-07-13
SI2425820T1 (sl) 2015-07-31
US20150057287A1 (en) 2015-02-26
KR20090129998A (ko) 2009-12-17
US20170196861A1 (en) 2017-07-13
EP2120875B1 (en) 2018-07-11
JP5825757B2 (ja) 2015-12-02
CY1116546T1 (el) 2017-03-15
AU2014203389B2 (en) 2016-08-11
US20190247393A1 (en) 2019-08-15
CA2677838C (en) 2017-08-01
ES2538082T3 (es) 2015-06-17
CA2677838A1 (en) 2008-08-14
HUE026884T2 (en) 2016-08-29
EP2425820B1 (en) 2015-04-08
MX2009008582A (es) 2009-10-30
PT2425820E (pt) 2015-08-04
HK1204918A1 (en) 2015-12-11
JP2016040316A (ja) 2016-03-24
US20200352939A1 (en) 2020-11-12
EP2425819A1 (en) 2012-03-07
US7994197B2 (en) 2011-08-09
AU2008214205B2 (en) 2014-04-24
US10172853B2 (en) 2019-01-08
US20100284940A1 (en) 2010-11-11
US20100081663A1 (en) 2010-04-01
US9833451B2 (en) 2017-12-05
JP2013224331A (ja) 2013-10-31
KR20150041804A (ko) 2015-04-17
PL2425820T3 (pl) 2015-08-31
US20100081664A1 (en) 2010-04-01
US20120245179A1 (en) 2012-09-27
JP6209198B2 (ja) 2017-10-04
US20080287451A1 (en) 2008-11-20
WO2008097664A1 (en) 2008-08-14
AU2016253689B2 (en) 2018-03-08
EP2120875A1 (en) 2009-11-25
JP5908439B2 (ja) 2016-04-26
CN104188907A (zh) 2014-12-10
ES2691033T3 (es) 2018-11-23
IL200333A0 (en) 2010-04-29
AU2014203389A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
US10172853B2 (en) Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
ZA200207420B (en) The treatment of respiratory diseases.